Journals / Journal of Experimental and Clinical Medicine / 2022 / Cilt: 39 - Sayı: 4

Evaluation Of Mammographic Features In Women With Adenomyosis

Pages
989–998
Publication Date
2022-10-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of our study suggested that patients with adenomyosis have an increased risk of higher mammographic breast density and BIRADS 3 classification.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Aim: This study aimed to investigate the mammographic features in women with adenomyosis to determine the relationship between adenomyosis and breast disease.
📊
Key Findings & Data:When patients with low mammographic density (Density A - B, n = 80) and high mammographic density (Density C - D, n = 60) were compared, there were no statistically significant differences between the groups except the presence of adenomyosis.
💡
Conclusion & Impact:Conclusion: The results of our study suggested that patients with adenomyosis have an increased risk of higher mammographic breast density and BIRADS 3 classification.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:BIRADS · Breast density · Uterine adenomyosis

Abstract

Abstract Aim: This study aimed to investigate the mammographic features in women with adenomyosis to determine the relationship between adenomyosis and breast disease. Methods: In this study, the mammographic features of women with adenomyosis were recorded. For the control group, women who had mammography without any gynaecologic complaints and with normal pelvic ultrasound were selected. Results: The adenomyosis group had higher breast density, more micro and macro calcifications, and higher BIRADS-mammography classification than the control group. When patients with low mammographic density (Density A - B, n = 80) and high mammographic density (Density C - D, n = 60) were compared, there were no statistically significant differences between the groups except the presence of adenomyosis. When patients were compared according to the BIRADS 1 - 2 (n=114) and BIRADS 3 - 4 (n=26) category, age ≥ 49.5, gravidity ≥ 3, parity ≥ 2, and the presence of adenomyosis were significantly higher in the BIRADS 3 - 4 category. In the logistic regression analysis, the presence of adenomyosis was found to be the sole factor for BIRADS 3-4 category. Conclusion: The results of our study suggested that patients with adenomyosis have an increased risk of higher mammographic breast density and BIRADS 3 classification.

🔖

Cite This Article

KADIOĞLU, N., YORGANCI, A., GÜMGÜMCÜ, H., KOKANALI, M. K., ÖZYER, Ş., ÜSTÜN, Y. (2022). Evaluation Of Mammographic Features In Women With Adenomyosis. Journal of Experimental and Clinical Medicine, Cilt: 39 - Sayı: 4, 989–998. https://ajindex.com/articles/886754

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Li X, Liu X, Guo SW.Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy.J Obstet Gynaecol Res.2014
  2. 40(2):485-94. 2.Szubert M, Kozirog E, et al.Adenomyosis and Infertility-Review of Medical and Surgical Approaches.Int J Environ Res Public Health.2021
  3. 18(3). 3.Protopapas A, Grimbizis G, et al.Adenomyosis: Disease, uterine aging process leading to symptoms, or both?Facts Views Vis Obgyn.2020
  4. 12(2):91-104. 4.Leyendecker G, Bilgicyildirim A, et al.Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation.Arch Gynecol Obstet.2015
  5. 291(4):917-32. 5.Donnez J, Donnez O, Dolmans MM.Uterine adenomyosis, another enigmatic disease of our time.Fertil Steril.2018
  6. 109(3):369-70. 6.Bourdon M, Santulli P, et al.Immunological changes associated with adenomyosis: a systematic review.Hum Reprod Update.2021
  7. 27(1):108-29. 7.Stratopoulou CA, Donnez J, Dolmans MM.Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far.Reprod Sci.2020. 8.Grebic D, Gulic T, et al.The Role of Innate Immunity in the Pathogenesis of Breast Cancer.Breast Care (Basel).2021
  8. 16(1):1-5. 9.Hilborn E, Stal O, Jansson A.Estrogen and androgen-converting enzymes 17beta-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17beta-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Oncotarget.2017
  9. 8(18):30552-62. 10.Spak DA, Plaxco JS, Santiago L, Dryden MJ, Dogan BE. BI-RADS((R)) fifth edition: A summary of changes. Diagn Interv Imaging.2017
  10. 98(3):179-90. 11.McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev.2006
  11. 15(6):1159-69. 12.Boyd NF, Martin LJ, et al. Breast tissue composition and susceptibility to breast cancer.J Natl Cancer Inst.2010
  12. 102(16):1224-37. 13.Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.J Clin Oncol.2010
  13. 28(24):3830-7. 14.Boyer B, Canale S, et al. Variability and errors when applying the BIRADS mammography classification.Eur J Radiol.2013
  14. 82(3):388-97. 15.Berg WA, Berg JM, et al. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.Radiology.2020
  15. 296(1):32-41. 16.Nagasawa H KR, Naito T, Ohmiya S, Mori T. Relationship between mammary t